Justin Petrone

The Danish rare cell diagnostics company is also in the process of migrating its tests from array comparative hybridization to next-generation sequencing.

CEO and Cofounder İbrahim Çağrı Kurt discussed the new test during a presentation at Slush, an annual startup conference held in Helsinki this week.

The Spanish company last week announced that it raised €13 million in Series B financing to fund its efforts to supplant culture-based methods with molecular testing.

The institute recently decided to create a new way to evaluate new tests, called the Early Value Assessment program, which has a six-month turnaround time.

If commercialized, the assay will mark Lucira's entry into market for at-home diagnostics for sexually transmitted infections.

The Digital Innovations and Diagnostics for Infectious Diseases in Africa project kicked off this month and will run through September 2027 with a budget of about €6 million.

The envisioned labs could be used to test emerging pathogens in the field using advanced molecular technologies, such as PCR and next-generation sequencing.

Called WID-qEC, the test uses quantitative PCR methylation profiling to diagnose endometrial cancer in women presenting with symptoms.

As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.

The partnership will see the two companies scour a Norwegian biobank for data that could produce a multitude of new aging-related tests, therapies, and perhaps companion diagnostics.